Skip to content
Tobias Sjoblom.jpg

Image -

Tobias Sjoblom.jpg

Tobias Sjöblom, professor at the Department of Immunology, Genetics and Pathology at Uppsala University.
Mikael Wallerstedt
License:
Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
By:
Mikael Wallerstedt
File format:
.jpg
Size:
3562 x 2519, 1.05 MB
Download

Topics

Contacts

Related content

  • Luis Nunes, researcher at the Department of Immunology, Genetics and Pathology at Uppsala University and one of the first authors of the study. Photo: Mikael Wallerstedt

    Genetic signatures provide prognostic information in colorectal cancer

    Using a unique collection of genetic and clinical data for colorectal cancer, researchers at Uppsala University have revealed genetic new alterations and developed of a new molecular classifier of tumour variants. The finding could lead to improved possibilities for individualised therapies. This is shown in study recently published in the journal Nature.

  • A graphical summary illustrates the strategy used to identify CYP2D6 as a target for collateral lethality, which is driven by the widespread occurrence of loss of heterozygosity in cancer genomes.

    Genetic variation enhances cancer drug sensitivity

    By exploiting the genetic variation in cancer cells, an already approved cancer drug demonstrated enhanced effects against cancer cells in specific patient groups. This is shown in a recent study from Uppsala University, published in the journal eBiomedicine. The findings suggest a potential for more individually tailored and more effective cancer therapies.